Alejo Chorny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/418443/publications.pdf

Version: 2024-02-01

41 papers

3,613 citations

28 h-index 289244 40 g-index

43 all docs 43 docs citations

43 times ranked

4976 citing authors

#	Article	IF	CITATIONS
1	Gut T cell–independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells. Science Immunology, 2020, 5, .	11.9	40
2	The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells. Journal of Experimental Medicine, 2016, 213, 2167-2185.	8.5	69
3	Microbiota regulate the ability of lung dendritic cells to induce IgA class-switch recombination and generate protective gastrointestinal immune responses. Journal of Experimental Medicine, 2016, 213, 53-73.	8.5	94
4	Regulation and Function of Mucosal IgA and IgD. , 2015, , 683-700.		1
5	<i>SORT1</i> Mutation Resulting in Sortilin Deficiency and p75 ^{NTR} Upregulation in a Family With Essential Tremor. ASN Neuro, 2015, 7, 175909141559829.	2.7	28
6	Mo1771 Microbiota Regulate Lung Dendritic Cells Ability to Induce IgA Class Switch Recombination and Generate Protective Gastrointestinal Immune Responsesl±. Gastroenterology, 2015, 148, S-707-S-708.	1.3	0
7	CEACAM1-S: The Virtues of Alternative Splicing in Gut Immunity. Immunity, 2012, 37, 768-770.	14.3	2
8	B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature Immunology, 2012, 13, 170-180.	14.5	615
9	Regulation of frontline antibody responses by innate immune signals. Immunologic Research, 2012, 54, 4-13.	2.9	12
10	A gut triumvirate rules homeostasis. Nature Medicine, 2011, 17, 1549-1550.	30.7	6
11	Immunoglobulin Responses at the Mucosal Interface. Annual Review of Immunology, 2011, 29, 273-293.	21.8	309
12	Innate Signaling Networks in Mucosal IgA Class Switching. Advances in Immunology, 2010, 107, 31-69.	2.2	42
13	Neuropeptides Rescue Mice from Lethal Sepsis by Down-regulating Secretion of the Late-Acting Inflammatory Mediator High Mobility Group Box 1. American Journal of Pathology, 2008, 172, 1297-1302.	3.8	68
14	Ghrelin Protects against Experimental Sepsis by Inhibiting High-Mobility Group Box 1 Release and by Killing Bacteria. Journal of Immunology, 2008, 180, 8369-8377.	0.8	134
15	Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator. Current Pharmaceutical Design, 2007, 13, 1113-1139.	1.9	80
16	Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Annals of the Rheumatic Diseases, 2007, 66, 582-588.	0.9	70
17	Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders. Peptides, 2007, 28, 1833-1846.	2.4	32
18	Adrenomedullin Protects from Experimental Arthritis by Down-Regulating Inflammation and Th1 Response and Inducing Regulatory T Cells. American Journal of Pathology, 2007, 170, 263-271.	3.8	53

#	Article	IF	CITATIONS
19	Tuning inflammation with anti-inflammatory neuropeptides. Expert Opinion on Biological Therapy, 2007, 7, 461-478.	3.1	20
20	Therapeutic effect of urocortin on collagenâ€induced arthritis by downâ€regulation of inflammatory and Th1 responses and induction of regulatory T cells. Arthritis and Rheumatism, 2007, 56, 531-543.	6.7	67
21	Regulation of immune tolerance by anti-inflammatory neuropeptides. Nature Reviews Immunology, 2007, 7, 52-63.	22.7	204
22	Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2006, 168, 1179-1188.	3.8	91
23	Urocortin and Adrenomedullin Prevent Lethal Endotoxemia by Down-Regulating the Inflammatory Response. American Journal of Pathology, 2006, 168, 1921-1930.	3.8	80
24	Therapeutic Action of Ghrelin in a Mouse Model of Colitis. Gastroenterology, 2006, 130, 1707-1720.	1.3	235
25	Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regulatory Peptides, 2006, 137, 67-74.	1.9	28
26	Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood, 2006, 107, 3787-3794.	1.4	94
27	Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood, 2006, 107, 3632-3638.	1.4	138
28	Vasoactive Intestinal Peptide Generates CD4+CD25+ Regulatory T Cells in vivo: Therapeutic Applications in Autoimmunity and Transplantation. Annals of the New York Academy of Sciences, 2006, 1070, 190-195.	3.8	20
29	Vasoactive Intestinal Polypeptide Induces Regulatory Dendritic Cells That Prevent Acute Graft Versus Host Disease and Leukemia Relapse after Bone Marrow Transplantation. Annals of the New York Academy of Sciences, 2006, 1070, 226-232.	3.8	9
30	VIP Prevents Experimental Multiple Sclerosis by Downregulating Both Inflammatory and Autoimmune Components of the Disease. Annals of the New York Academy of Sciences, 2006, 1070, 276-281.	3.8	31
31	VIP: An Agent with License to Kill Infective Parasites. Annals of the New York Academy of Sciences, 2006, 1070, 303-308.	3.8	19
32	Regulation of Dendritic Cell Differentiation by Vasoactive Intestinal Peptide: Therapeutic Applications on Autoimmunity and Transplantation. Annals of the New York Academy of Sciences, 2006, 1088, 187-194.	3.8	30
33	Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagenâ€induced arthritis. Arthritis and Rheumatism, 2006, 54, 864-876.	6.7	93
34	Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. European Journal of Immunology, 2006, 36, 318-326.	2.9	83
35	Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut, 2006, 55, 824-832.	12.1	93
36	Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. Journal of Experimental Medicine, 2006, 203, 563-571.	8.5	156

ALEJO CHORNY

#	Article	IF	CITATION
37	Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4228-4233.	7.1	105
38	Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13562-13567.	7.1	151
39	Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. Journal of Leukocyte Biology, 2005, 78, 1327-1338.	3.3	99
40	Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opinion on Therapeutic Targets, 2005, 9, 923-929.	3.4	12
41	Bacterial DNA activates human neutrophils by a CpGâ€independent pathway. European Journal of Immunology, 2003, 33, 3164-3174.	2.9	96